Astellas Pharma (MEX:4503N) Cash Flow for Dividends: MXN-16,700 Mil (TTM As of Mar. 2026)


MEX:4503N Astellas Pharma Inc MEX:4503N
78 GF Score
Price MXN253.57
GF Value MXN246.87
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma Cash Flow for Dividends?

Astellas Pharma MEX:4503N 78 Cash Flow for Dividends is MXN-16,700 Mil as of Mar. 2026. GuruFocus rates MEX:4503N with a GF Score™ of 78/100 and a GF Value™ of MXN246.87 (Fairly Valued). The stock has 4 warning signs investors should review.

Astellas Pharma's cash flow for dividends for the three months ended in Mar. 2026 was MXN0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-16,700 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Astellas Pharma's quarterly payment of dividends increased from Sep. 2025 (MXN0 Mil) to Dec. 2025 (MXN-8,067 Mil) but then declined from Dec. 2025 (MXN-8,067 Mil) to Mar. 2026 (MXN0 Mil).

Astellas Pharma's annual payment of dividends increased from Mar. 2024 (MXN-12,922 Mil) to Mar. 2025 (MXN-17,704 Mil) but then declined from Mar. 2025 (MXN-17,704 Mil) to Mar. 2026 (MXN-15,466 Mil).

Astellas Pharma Cash Flow for Dividends Related Terms

Astellas Pharma Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Cash Flow for Dividends Chart

Astellas Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14,312.46 -13,533.15 -12,922.31 -17,704.33 -15,466.29

Astellas Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -8,632.58 0.00 -8,067.49 0.00
MEX:4503N
78GF Score
Astellas Pharma Inc MEX:4503N
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astellas Pharma Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-16,700 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of MXN-16,700 Mil mean?
Astellas Pharma (MEX:4503N) has a Cash Flow for Dividends of MXN-16,700 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Astellas Pharma and its competitors.
Is Astellas Pharma's Cash Flow for Dividends too high?
Astellas Pharma's current Cash Flow for Dividends is MXN-16,700 Mil. Overall, Astellas Pharma has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Cash Flow for Dividends compare to LLY and JNJ?
Astellas Pharma's Cash Flow for Dividends of MXN-16,700 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Drug Manufacturers company?
A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Astellas Pharma and its competitors. Astellas Pharma's current Cash Flow for Dividends is MXN-16,700 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (MEX:4503N) is currently considered Fairly Valued. The stock's GF Value™ is MXN246.87, compared to a current price of MXN253.57 — trading 2.7% above its estimated fair value. The current Cash Flow for Dividends is MXN-16,700 Mil. Astellas Pharma's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Astellas Pharma (MEX:4503N), the current Cash Flow for Dividends is MXN-16,700 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (MEX:4503N) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be overvalued. The current stock price of MXN253.57 is trading 2.7% above its estimated GF Value™ of MXN246.87. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for MEX:4503N:

  • Cash Flow for Dividends: MXN-16,700 Mil
  • GF Value™: MXN246.87 vs. price of MXN253.57 (2.7% above fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the MEX:4503N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
78GF Score

Get the complete analysis for MEX:4503N

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN253.57
Price
MXN246.87
GF Value